Literature DB >> 10652644

Evaluation of established rheumatoid arthritis.

A M van Gestel1, G Stucki.   

Abstract

There are two major aspects to evaluate in patients with established RA, namely (i) the state or progress of the disease, and (ii) the effects of specific interventions. The evaluation should include reliable, valid and sensitive measures of disease activity, tissue damage and health status. It is important to recognise that measures of disease activity can be influenced by tissue damage as well. Also, in established RA, health status is likely to be influenced by both disease activity and tissue damage. Whether current rules concerning improvement or remission, which were developed in the context of early RA, can be applied to established disease has to be investigated. While use of radiographs is the current standard method of assessing damage in established RA, range-of-motion measures and muscle strength indices may be a more practical and an equally valid alternative. When selecting health status instruments one should carefully explore and pretest possible health status measures for specific clinical or study settings.

Entities:  

Mesh:

Year:  1999        PMID: 10652644     DOI: 10.1053/berh.1999.0050

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  2 in total

1.  Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis?

Authors:  Linda Mary Davies; Emily Anne Fargher; Karen Tricker; Peter Dawes; David L Scott; Deborah Symmons
Journal:  Ann Rheum Dis       Date:  2006-11-23       Impact factor: 19.103

2.  Severe deficiency of 25-hydroxyvitamin D₃ (25-OH-D₃) is associated with high disease activity of rheumatoid arthritis.

Authors:  Hans-Jacob Haga; Anne Schmedes; Yusuf Naderi; Alicia Martin Moreno; Elisabeth Peen
Journal:  Clin Rheumatol       Date:  2013-01-15       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.